Company Estimates Cash Runway Sufficient to Report Top-Line Results from Two of Three Patient Groups in Phase 2 Trials By 4th Quarter of Calendar Year 2020
SAN DIEGO, Sept. 10, 2019 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMa… […]
MARINA DEL REY, Calif., Aug. 14, 2019 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resi… […]
SAN DIEGO and VANCOUVER, British Columbia, Aug. 9, 2019 /PRNewswire/ — Sophiris Bio Inc. (NASDAQ: SPHS) (the “Company” or “Sophiris”), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage c… […]
Company to Host Conference Call with Analysts to Review Financial Results and Provide Update on the NKTR-214 (bempegaldesleukin) Program
SAN FRANCISCO, Aug. 8, 2019 /PRNewswire/ — Nektar Therapeutics (Nasdaq: NKTR) today reported its financial resu… […]
Closing of First Tranche of $41.8 Million Private Placement of EquityTerm Loan Restructured Providing Up to Two Years of Interest Only and Extended Maturity Date to May 2022Data Requirements Defined to Reinitiate Multiple Ascending Dose and Chronic Dos… […]
Closing of First Tranche of $41.8 Million Private Placement of EquityTerm Loan Restructured Providing Up to Two Years of Interest Only and Extended Maturity Date to May 2022Data Requirements Defined to Reinitiate Multiple Ascending Dose and Chronic Dos… […]
SAN DIEGO, Aug. 8, 2019 /PRNewswire/ — Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing potentially best-in-class oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today … […]
— Preliminary Phase 2 results for hepcidin mimetic PTG-300 in beta-thalassemia are expected in the fourth quarter of 2019 —- Phase 2 study of PTG-300 in polycythemia vera expected to begin in the third quarter of 2019; studies in hereditary hemochro… […]
– Total Revenues Increase 11% to $39.1 Million Compared to $35.2 Million in Prior-year Period — ENHANZE® Partner Janssen Submits Regulatory Applications for Subcutaneous Formulation of DARZALEX® in the U.S. and EU — Pivotal Phase 3 Trial Results from… […]
SAN DIEGO, Aug. 5, 2019 /PRNewswire/ — Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the second quarter ended June 30, 2019.
Second Quarter Highlights:
Initiated the Phase… […]
Copyright © 2019 San Diego Biotechnology Network (DBA of Comprendia. LLC)
